These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 29175080

  • 21. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
    Huang X, Wang M, Wang C, Hu W, You Q, Yang Y, Yu C, Liao Z, Gou S, Wang H.
    Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
    [Abstract] [Full Text] [Related]

  • 22. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
    Xu Z, Wang Z, Yiu SM, Zhu G.
    Dalton Trans; 2015 Dec 14; 44(46):19918-26. PubMed ID: 26514681
    [Abstract] [Full Text] [Related]

  • 23. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z, Xu Z, Zhu G.
    Angew Chem Int Ed Engl; 2016 Dec 12; 55(50):15564-15568. PubMed ID: 27736029
    [Abstract] [Full Text] [Related]

  • 24. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
    Xiao H, Noble GT, Stefanick JF, Qi R, Kiziltepe T, Jing X, Bilgicer B.
    J Control Release; 2014 Jan 10; 173():11-7. PubMed ID: 24511610
    [Abstract] [Full Text] [Related]

  • 25. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F, Qin X, Xu G, Gou S, Jin X.
    Biochem Pharmacol; 2017 Jul 01; 135():50-68. PubMed ID: 28288821
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
    Ravera M, Gabano E, Bonzani D, Zanellato I, Arrais A, Cantamessa S, Biggiogera M, Osella D.
    J Inorg Biochem; 2018 Dec 01; 189():185-191. PubMed ID: 30312905
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Nanoparticle-mediated delivery of multinuclear platinum(IV) prodrugs with enhanced drug uptake and the activity of overcoming drug resistance.
    Gao Y, Jiang M, Ma Y, Wu S, Li W, Yang X, Li Y, Jing X, Jiang H.
    Anticancer Drugs; 2016 Feb 01; 27(2):77-83. PubMed ID: 26473527
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and Cytotoxic Study of a Platinum(IV) Anticancer Prodrug with Selectivity toward Luteinizing Hormone-Releasing Hormone (LHRH) Receptor-Positive Cancer Cells.
    Yao H, Xu Z, Li C, Tse MK, Tong Z, Zhu G.
    Inorg Chem; 2019 Aug 19; 58(16):11076-11084. PubMed ID: 31393117
    [Abstract] [Full Text] [Related]

  • 32. Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles.
    Kalayda GV, Jansen BA, Wielaard P, Tanke HJ, Reedijk J.
    J Biol Inorg Chem; 2005 May 19; 10(3):305-15. PubMed ID: 15824924
    [Abstract] [Full Text] [Related]

  • 33. Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance.
    Papadia P, Micoli K, Barbanente A, Ditaranto N, Hoeschele JD, Natile G, Marzano C, Gandin V, Margiotta N.
    Int J Mol Sci; 2020 Mar 27; 21(7):. PubMed ID: 32230896
    [Abstract] [Full Text] [Related]

  • 34. Synergic highly effective photothermal-chemotherapy with platinum prodrug linked melanin-like nanoparticles.
    Zhang C, Zhao X, Guo H.
    Artif Cells Nanomed Biotechnol; 2018 Mar 27; 46(sup2):356-363. PubMed ID: 29607699
    [Abstract] [Full Text] [Related]

  • 35. Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.
    Najjar A, Rajabi N, Karaman R.
    Curr Pharm Des; 2017 Mar 27; 23(16):2366-2376. PubMed ID: 28155621
    [Abstract] [Full Text] [Related]

  • 36. NIR Light and GSH Dual-Responsive Upconversion Nanoparticles Loaded with Multifunctional Platinum(IV) Prodrug and RGD Peptide for Precise Cancer Therapy.
    Liu XM, Zhu ZZ, He XR, Zou YH, Chen Q, Wang XY, Liu HM, Qiao X, Wang X, Xu JY.
    ACS Appl Mater Interfaces; 2024 Aug 07; 16(31):40753-40766. PubMed ID: 39046129
    [Abstract] [Full Text] [Related]

  • 37. Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor.
    Li Y, Deng Y, Tian X, Ke H, Guo M, Zhu A, Yang T, Guo Z, Ge Z, Yang X, Chen H.
    ACS Nano; 2015 Oct 27; 9(10):9626-37. PubMed ID: 26365698
    [Abstract] [Full Text] [Related]

  • 38. Platin-C containing nanoparticles: a recipe for the delivery of curcumin-cisplatin combination chemotherapeutics to mitochondria.
    Banik B, Ashokan A, Choi JH, Surnar B, Dhar S.
    Dalton Trans; 2023 Mar 21; 52(12):3575-3585. PubMed ID: 36723189
    [Abstract] [Full Text] [Related]

  • 39. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
    Ravera M, Perin E, Gabano E, Zanellato I, Panzarasa G, Sparnacci K, Laus M, Osella D.
    J Inorg Biochem; 2015 Oct 21; 151():132-42. PubMed ID: 26277416
    [Abstract] [Full Text] [Related]

  • 40. Carboplatin prodrug conjugated Fe3O4 nanoparticles for magnetically targeted drug delivery in ovarian cancer cells.
    Song H, Quan F, Yu Z, Zheng M, Ma Y, Xiao H, Ding F.
    J Mater Chem B; 2019 Jan 21; 7(3):433-442. PubMed ID: 32254730
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.